Genotoxic evaluation of pirfenidone using erythrocyte rodent micronucleus assay

Food and Chemical Toxicology

Volumn 50, Issue 8, 2012, Pages 2760-2765

  Alcántar Díaz, Blanca E ^a   Gómez Meda, Belinda C ^a   Zúñiga González, Guillermo M ^b   Zamora Perez, Ana L ^a   González Cuevas, Jaime ^a   Álvarez Rodríguez, Bertha A ^a   Sánchez Parada, María Guadalupe ^a   García Bañuelos, Jesús J ^a   Armendáriz Borunda, Juan ^a,c  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

Antioxidant; DNA damage; Fibrosis; Micronuclei; Pyridone; Rodent

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; PIRFENIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIRTH; BLOOD SMEAR; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ERYTHROCYTE; FEMALE; GENOTOXICITY; GESTATIONAL AGE; LOW DRUG DOSE; MALE; MICRONUCLEUS TEST; MOUSE; NEWBORN; NONHUMAN; PLACENTAL TRANSFER; PREGNANCY; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ERYTHROCYTES; FEMALE; MALE; MICE; MICE, INBRED BALB C; MICRONUCLEUS TESTS; MUTAGENS; PREGNANCY; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY;

MUS; RATTUS; RODENTIA;

EID: 84862669156     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.05.049     Document Type: Article

References (37)

1. APA: The American psychological association guidelines for ethical conduct in the care and use of animals, 2011. Downloaded from: http://www.apa.org/science/anguide.html.
2. Armendáriz-Borunda J., Islas-Carbajal M.C., Meza-García E., Rincón A.R., Lucano S., Sandoval A.S., Salazar A., Berumen J., álvarez A., Covarrubias A., Aréchiga G., García L. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006, 55(11):1663-1665.
3. Armendáriz-Borunda J., Lyra-González I., Medina-Preciado D., González-García I., Martínez-Fong D., Miranda R.A., Magaña-Castro R., Peña-Santoyo P., García-Rocha S., Bautista C.A., Godoy J., Flores-Montana J., Floresvillar-Mosqueda J., Armendáriz-Vázquez O., Lucano-Landeros M.S., Vázquez-Del Mercado M., Sánchez-Parada M.G. A controlled trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann. Plastic Surg. 2011, 68(1):22-28.
4. Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev. Respir. Med. 2010, 4(3):301-310.
5. Babovic-Vuksanovic D., Widemann B.C., Dombi E., Gillespie A., Wolters P.L., Toledo-Tamula M.A., O'Neill B.P., Fox E., MacDonald T., Beck H., Packer R.J. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr. Neurol. 2007, 36(5):293-300.
6. Benton H.P., Esquivel A.V., Rice A.D., Giri S.N. Modulation of articular chondrocyte activity by pirfenidone. Res. Commun. Mol. Pathol. Pharmacol. 2003, 113-114:275-288.
7. Cho M.E., Kopp J.B. Pirfenidone: an antifibrotic therapy for progressive kidney disease. Expert Opin. Investig. Drugs 2010, 19(2):275-283.
8. DOF: Diario Oficial de la Federación, 2001. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio, Secretaria de Agricultura, Ganadería, Desarrollo Rural, Pesca y Alimentación. Norma Oficial Mexicana NOM-062-ZOO-1999.
9. García L., Hernandez I., Sandoval A., Salazar A., García J., Vera J., Grijalva G., Muriel P., Margolin S., Armendáriz-Borunda J. Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. 2002, 37(6):797-805.
10. Giri S.N., Leonard S., Shi X., Margolin S.B., Vallyathan V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. 1999, 18(3):169-177.
11. Gomer R.H., Lupher M.L. Investigational approaches to therapies for idiophatic pulmonary fibrosis. Expert Opin. Investig. Drugs 2010, 19(6):737-745.
12. Gómez-Meda B.C., Zúñiga-González G.M., Zamora-Perez A., Ramos-Ibarra M.L., Batista-González C.M., Torres-Mendoza B.M. Folate supplementation of cyclophosphamide-treated mothers diminishes micronucleated erythrocytes in peripheral blood of newborn rats. Environ. Mol. Mutagen. 2004, 44(2):174-178.
13. Gómez-Meda B.C., Zamora-Perez A.L., Zúñiga-González G.M. Genotoxicity and biomonitoring: micronuclei in peripheral blood and epithelial cells. New Research on DNA Damage 2008, 145-182. Nova Science Publishers, Inc., New York, USA. H. Kimura, A. Suzuki (Eds.).
14. Hayashi M., MacGregor J.T., Gatehouse D.G., Adler I.D., Blakey D.H., Dertinger S.D., Krishna G., Morita T., Russo A., Sutou S. In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring. Environ. Mol. Mutagen. 2000, 35(3):234-252.
15. Hayashi M., Sofuni T. The need for three dose levels to detect genotoxic chemicals in in vivo rodent assays. Mutat. Res. 1995, 327(1-2):247-251.
16. ICH, 2011. Topic S2B genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals. International Conference on the Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Step 4. Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). Downloaded from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf.
17. Karimi-Shah, B.A., 2011. Clinical Briefing Document NDA 22-535 Esbriet®, Pirfenidone Capsules., Summary of Product Characteristics (SmPC)-Esbriet, Intermune UK & I Ltd., Marketing, Division of Pulmonary and Allergy Products. Approval in the European Union March 3, 2011. Downloaded from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf.
18. Klaassen C.D. Casarett & Doull's Toxicology, the Basic Science of Poisons 2001, McGraw-Hill, New York, USA, pp. 1236. sixth edition.
19. Macías-Barragán J., Sandoval-Rodríguez A., Navarro-Partida J., Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010, 3:16.
20. Misra H.P., Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. 2000, 204(1-2):119-126.
21. Nakanishi H., Kairobi M., Teshima S., Yoshida H., Kwon A.H., Kamiyama Y., Nishizawa M., Ito S., Okumura T. Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. J. Hepatol. 2004, 41(5):730-736.
22. OECD (Organisation of Economic Cooperation and Development), 1997. Test No. 474: Mammalian Erythrocyte Micronucleus Test, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing, Paris, France. Downloaded from: http://www.oecd.org/dataoecd/18/34/1948442.pdf.
23. Oku H., Shimizu T., Kawabata T., Nagira M., Hikita I., Ueyama A., Matsushima S., Torii M., Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008, 590(1-3):400-408.
24. Poole T. The UFAW handbook on the care & management of laboratory animals 1994, Longman Scientific & Technical, Essex, England, pp. 948. sixth edition.
25. Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease. Clin. Liver Dis. 2008, 12(4):939-962.
26. Salazar-Montes A., Ruiz-Corro L., Lopez-Reyes A., Castrejón-Gómez E., Armendáriz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur. J. Pharmacol. 2008, 595(1-3):69-77.
27. Shi S., Wu J., Chen H., Chen H., Wu J., Zeng F. Single- and multiple-dose pharmacokinetics of pirfenidone, and antifibrotic agent, in healthy Chinese volunteers. J. Clin. Pharmacol. 2007, 47(10):1268-1276.
28. Simone N.L., Soule B.P., Gerber L., Augustine E., Smith S., Altemus R.M., Mitchell J.B., Camphausen K.A. Oral Pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study Radiat. Oncology 2007, 2:19-24.
29. Taniyama M., Ohbayashi S., Narita M., Nakazawa R., Hasegawa S., Azuma N., Teraoka S., Ota K., Yamauchi S., Margolin S.B. Pharmacokinetics of an antifibrogen agent, pirfenidone, in haemodialysis patients. Eur. J. Clin. Pharmacol. 1997, 52(1):77-78.
30. Vanparys P., Deknudt G., Vermeiren F., Sysmans M., Marsboom R. Sampling times in micronucleus testing. Mutat. Res. 1992, 282(3):191-196.
31. Veras-Castillo, E.R., Cárdenas-Camarena, L., Lyra-González, I., Muñoz-Valle, J.F., Lucano-Landeros, S., Guerrerosantos, J., González-Ulloa, B., Mercado-Barajas, J.L., Sánchez-Parada, M.G., Azabache-Wennceslao, R., Armendáriz-Borunda, J., 2012. Controlled clinical trial with pirfenidone in the treatment of breast capsular contracture. Association of TGF-β polymorphisms. Ann. Plastic Surg., in press. http://dx.doi.org/10.1097/SAP.0b013e31822284f4.
32. Visner G.A., Liu F., Bizargity P., Liu H., Liu K., Yang J., Wang L., Hancock W.W. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation 2009, 88(3):330-338.
33. Zhao X.Y., Zeng X., Li X.M., Wang T.L., Wang B.E. Pirfenidone inhibits carbon tetrachloride- and albumin complex- induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin. Exp. Pharmacol. Physiol. 2009, 36(10):963-968.
34. Zúñiga-González G., Gómez-Meda B.C., Zamora-Perez A., Ramos-Ibarra M.L., Batista-González C.M., Espinoza-Jiménez S., Gallegos-Arreola M.P., álvarez-Moya C., Torres-Bugarín O. Induction of micronuclei in proestrus vaginal cells from colchicine- and cyclophosphamide-treated rats. Environ. Mol. Mutagen. 2003, 42(4):306-310.
35. Zúñiga-González G.M., Torres-Bugarín O., Zamora-Perez A.L., Gómez-Meda B.C., Ramos-Ibarra M.L., Gallegos-Arreola P., Flores-García A., López-Uribe A. Induction of micronucleated erythrocytes in mouse peripheral blood after cutaneous application of 5-fluorouracil. Arch. Med. Res. 2003, 34(2):141-144.
36. Zúñiga-González G.M., Batista-González C.M., Gómez-Meda B.C., Ramos-Ibarra M.L., Zamora-Perez A.L., Muñoz-Magallanes T., Ramos-Valdés C., Gallegos-Arreola M.P. Micronuclei in diabetes: folate supplementation diminishes micronuclei in diabetic patients but not in an animal model. Mutat. Res. 2007, 634(1-2):126-134.
37. Zúñiga-González G.M., Gómez-Meda B.C., Zamora-Perez A.L., Gallegos-Arreola M.P. Genotoxicity produced by disease and drugs. Genotoxicity: Evaluation, Testing and Prediction 2009, 127-156. Nova Science Publishers, Inc., New York, USA. A. Kocsis, H. Molnar (Eds.).